AG˹ٷ

STOCK TITAN

Standard BioTools Reports First Quarter 2025 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Standard BioTools (NASDAQ: LAB) reported Q1 2025 financial results with revenue of $40.8 million, down 10% year-over-year. The company achieved a 45% reduction in operating loss and 29% improvement in adjusted EBITDA. Key financial metrics include: consumables revenue of $14.5M (down 16%), instruments revenue of $7.8M (up 24%), and services revenue of $17.6M (down 16%). The company maintains a strong balance sheet with $261 million in cash and no material debt. Operating expenses decreased by 38% to $52.7M, while net loss improved by 19% to $26.0M. Standard BioTools reaffirmed its full-year 2025 revenue guidance of $165-175 million, factoring in expected NIH funding pressures in Americas academic revenue.
Standard BioTools (NASDAQ: LAB) ha riportato i risultati finanziari del primo trimestre 2025 con un fatturato di 40,8 milioni di dollari, in calo del 10% rispetto all'anno precedente. L'azienda ha ottenuto una riduzione del 45% della perdita operativa e un miglioramento del 29% dell'EBITDA rettificato. I principali indicatori finanziari includono: ricavi da consumabili pari a 14,5 milioni di dollari (in calo del 16%), ricavi da strumenti pari a 7,8 milioni di dollari (in aumento del 24%) e ricavi da servizi pari a 17,6 milioni di dollari (in calo del 16%). L'azienda mantiene un bilancio solido con 261 milioni di dollari in liquidità e nessun debito significativo. Le spese operative sono diminuite del 38%, attestandosi a 52,7 milioni di dollari, mentre la perdita netta è migliorata del 19%, raggiungendo i 26,0 milioni di dollari. Standard BioTools ha confermato la guidance per il fatturato dell'intero anno 2025, prevista tra 165 e 175 milioni di dollari, tenendo conto delle pressioni previste sui finanziamenti NIH nel settore accademico delle Americhe.
Standard BioTools (NASDAQ: LAB) reportó los resultados financieros del primer trimestre de 2025 con ingresos de 40,8 millones de dólares, una disminución del 10% interanual. La compañía logró una reducción del 45% en la pérdida operativa y una mejora del 29% en el EBITDA ajustado. Los principales indicadores financieros incluyen: ingresos por consumibles de 14,5 millones de dólares (bajaron un 16%), ingresos por instrumentos de 7,8 millones de dólares (aumentaron un 24%) e ingresos por servicios de 17,6 millones de dólares (bajaron un 16%). La empresa mantiene un balance sólido con 261 millones de dólares en efectivo y sin deuda significativa. Los gastos operativos disminuyeron un 38%, hasta 52,7 millones de dólares, mientras que la pérdida neta mejoró un 19%, situándose en 26,0 millones de dólares. Standard BioTools reafirmó su guía de ingresos para todo el año 2025, estimada entre 165 y 175 millones de dólares, considerando las presiones esperadas en la financiación NIH en los ingresos académicos de las Américas.
Standard BioTools(NASDAQ: LAB)� 2025� 1분기 실적� 발표하며 매출액이 4,080� 달러� 전년 동기 대� 10% 감소했다� 밝혔습니�. 회사� 영업 손실� 45% 줄였� 조정 EBITDA� 29% 개선했습니다. 주요 재무 지표로� 소모� 매출 1,450� 달러(16% 감소), 기기 매출 780� 달러(24% 증가), 서비� 매출 1,760� 달러(16% 감소)가 있습니다. 회사� 2� 6,100� 달러� 현금� 보유하고 있으� 실질적인 부채는 없습니다. 영업비용은 38% 감소� 5,270� 달러였� 순손실은 19% 개선되어 2,600� 달러� 기록했습니다. Standard BioTools� 미주 지� 학술 수익� NIH 자금 압박� 반영하여 2025� 연간 매출 가이던스를 1� 6,500만~1� 7,500� 달러� 재확인했습니�.
Standard BioTools (NASDAQ : LAB) a publié ses résultats financiers du premier trimestre 2025, avec un chiffre d'affaires de 40,8 millions de dollars, en baisse de 10 % par rapport à l'année précédente. La société a réalisé une réduction de 45 % de sa perte opérationnelle et une amélioration de 29 % de son EBITDA ajusté. Les principaux indicateurs financiers comprennent : un chiffre d'affaires consommables de 14,5 millions de dollars (en baisse de 16 %), un chiffre d'affaires instruments de 7,8 millions de dollars (en hausse de 24 %) et un chiffre d'affaires services de 17,6 millions de dollars (en baisse de 16 %). L'entreprise maintient un bilan solide avec 261 millions de dollars de liquidités et aucune dette significative. Les dépenses d'exploitation ont diminué de 38 % pour s'établir à 52,7 millions de dollars, tandis que la perte nette s'est améliorée de 19 % pour atteindre 26,0 millions de dollars. Standard BioTools a confirmé ses prévisions de chiffre d'affaires pour l'ensemble de l'année 2025, entre 165 et 175 millions de dollars, en tenant compte des pressions attendues sur le financement NIH dans les revenus académiques des Amériques.
Standard BioTools (NASDAQ: LAB) meldete die Finanzergebnisse für das erste Quartal 2025 mit einem Umsatz von 40,8 Millionen US-Dollar, was einem Rückgang von 10 % im Jahresvergleich entspricht. Das Unternehmen erreichte eine Reduzierung des operativen Verlusts um 45 % und eine Verbesserung des bereinigten EBITDA um 29 %. Wichtige Finanzkennzahlen sind: Verbrauchsmaterial-Umsatz von 14,5 Mio. USD (minus 16 %), Geräteumsatz von 7,8 Mio. USD (plus 24 %) und Serviceumsatz von 17,6 Mio. USD (minus 16 %). Das Unternehmen verfügt über eine starke Bilanz mit 261 Millionen US-Dollar in bar und keiner wesentlichen Verschuldung. Die Betriebskosten sanken um 38 % auf 52,7 Mio. USD, während der Nettoverlust um 19 % auf 26,0 Mio. USD verbessert wurde. Standard BioTools bestätigte seine Umsatzprognose für das Gesamtjahr 2025 von 165 bis 175 Millionen US-Dollar unter Berücksichtigung erwarteter NIH-Finanzierungsdrucke im akademischen Umsatz der Amerikas.
Positive
  • 45% reduction in operating loss year-over-year
  • 29% improvement in adjusted EBITDA compared to Q1 2024
  • Strong balance sheet with $261M cash and no material debt
  • 24% year-over-year growth in instruments revenue
  • Operationalized additional $10M in annual cost reductions, totaling $90M since merger
  • 38% decrease in operating expenses to $52.7M
Negative
  • 10% year-over-year decline in total revenue to $40.8M
  • 16% decrease in consumables revenue
  • 16% decline in services revenue
  • Gross margin decreased to 48.4% from 53.1% year-over-year
  • Net loss of $26.0M despite improvements
  • Anticipated decline in Americas academic revenue due to NIH funding pressures

Insights

Despite revenue decline, Standard BioTools shows progress in cost reduction and EBITDA improvement while maintaining strong cash position during industry challenges.

Standard BioTools' Q1 2025 results reflect a company in transition, balancing revenue challenges with impressive operational efficiency gains. The 10% year-over-year revenue decline to $40.8 million signals ongoing market headwinds, but management's cost-cutting initiatives are yielding tangible results. The 45% reduction in operating loss and 29% improvement in adjusted EBITDA demonstrate effective execution of their efficiency strategy.

The revenue breakdown reveals important dynamics: while instruments grew 24% thanks to the Hyperion XTi platform, both consumables (-16%) and services (-16%) declined significantly. This pattern suggests customers are purchasing capital equipment but potentially limiting ongoing consumable usage - a concerning indicator for recurring revenue streams. Gross margin compression from 53.1% to 48.4% further points to pricing pressures and unfavorable product mix.

The company's operational discipline is evident in their $90 million cost reduction achievements since merger. Operating expenses decreased dramatically by 38% to $52.7 million, directly improving bottom-line results. With $261 million in cash and minimal debt, Standard BioTools maintains significant financial flexibility to weather industry challenges.

Management's maintained revenue guidance of $165-175 million for 2025 indicates stability in their outlook despite Q1 headwinds. Their specific caution about NIH funding pressures affecting academic revenue suggests targeted challenges rather than broad-based market deterioration. The strategic focus on proteomics technology, particularly upcoming launches with Illumina, represents a potential growth catalyst amid otherwise challenging conditions.

Standard BioTools strategically positions in proteomics with SomaScan tech and Illumina partnership while navigating revenue challenges through operational efficiency.

Standard BioTools is making a calculated strategic pivot toward proteomics technologies while managing through industrywide funding pressures. The 24% growth in instrument revenue driven by their Hyperion XTi spatial proteomics platform is particularly significant against the backdrop of overall revenue decline. This platform enables high-plex protein imaging at subcellular resolution, addressing a critical need in translational and clinical research.

Most notable is management's emphasis on their SomaScan and SOMAmer technology. These aptamer-based proteomics approaches offer distinct advantages over traditional antibody methods, particularly in throughput, reproducibility, and dynamic range. The mention of validation at AACR (American Association for Cancer Research) suggests growing adoption in oncology applications, where multi-protein signatures are increasingly valuable for both diagnostic and therapeutic development.

The upcoming NGS-based proteomics product launch with Illumina represents a potentially transformative development. By integrating proteomics with Illumina's dominant sequencing infrastructure, Standard BioTools could significantly expand their addressable market by lowering barriers to proteomics adoption. This approach effectively piggybacks on existing sequencing workflows rather than requiring completely separate instrumentation.

However, the 16% decline in consumables revenue indicates challenges in driving recurring usage of their platforms. In the proteomics space, where reagent and assay costs typically outweigh instrumentation over lifetime value, this trend merits close monitoring. The company appears to be betting that their technological advantages in proteomics will eventually drive stronger consumable pull-through as the methodology becomes further established in population-scale studies, though short-term headwinds from research funding environments remain a significant challenge.

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB)(the “Company� or “Standard BioTools�) today announced financial results for the first quarter ended March 31, 2025.

Recent Highlights:

  • First quarter 2025 revenue of $40.8 million
  • 45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-year
  • Operationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger
  • Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025

“Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a challenging Life Sciences macro backdrop,� said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "We remain grounded and disciplined, driving a 29% year-over-year improvement in adjusted EBITDA through Standard BioTools Business System (SBS). We believe our unique model, world class operational platform and healthy capital position will allow us to continue to take advantage of the current environment and deliver shareholder value over time.�

Dr. Egholm added, "On a product level, I am particularly excited by our strategic foothold in proteomics and the momentum building for SomaScan and SOMAmers. The advantages and performance over legacy antibody-based approaches is now well-documented, most recently at the AACR Annual Meeting and through a growing list of publications. As population-based proteomics studies continue to favor our technology, the upcoming launch of our Illumina partnered NGS-based product will only further expand access. Together we expect this momentum to accelerate as we help usher in an exciting new era of proteomic discovery.


Financial Results Table:

Three Months Ended March31,
(Unaudited, in millions, except percentages)20252024
Revenue$40.8$45.5
Gross margin48.4%53.1%
Non-GAAP gross margin53.2%56.2%
Operating expenses$52.7$84.4
Non-GAAP operating expenses$38.6$49.3
Operating loss$(33.0)$(60.2)
Net loss$(26.0)$(32.2)
Adjusted EBITDA$(16.9)$(23.7)
Cash, cash equivalents, restricted cash, and short-term investments$260.70$463.6

First Quarter 2025 Financial Results

  • Revenue was $40.8 million in the first quarter of 2025, down 10% year-over-year:
    • Consumables revenue was $14.5 million in the first quarter of 2025, down 16% year-over-year. Consumables revenue declined due to lower volume.
    • Instruments revenue was $7.8 million in the first quarter of 2025, up 24% year-over-year. Instrument revenue was driven by strong growth in our Hyperion XTi spatial proteomics platform.
    • Services revenue, which includes both Lab Services and Field Services, was $17.6 million in the first quarter of 2025, down 16% year-over-year. Lab Services revenue was down 19% due to a tough comparable to prior-year levels that benefited from elevated backlog as well as project timing.
  • Gross margins in the first quarter of 2025 were 48.4%, versus 53.1% in the first quarter of 2024; and non-GAAP gross margins, which exclude depreciation, amortization, and stock-based compensation, were 53.2% in the first quarter of 2025 versus 56.2% in the first quarter of 2024. Gross margins were impacted by lower volume, price realization and product mix, partially offset by incremental improvements from SBS.
  • Operating expenses in the first quarter of 2025 were $52.7 million, a decrease of$31.7 million, or down 38%, compared to the first quarter of 2024; and non-GAAP operating expenses, which exclude merger-related costs, stock-based compensation, and restructuring charges, were $38.6 million in the first quarter of 2025, a decrease of $10.7 million, or down 22%, compared to the first quarter of 2024. The decrease in operating expenses is a result of the realization of merger cost synergies and continued productivity gains from SBS.
  • Net loss for the first quarter of 2025 was $26.0 million, compared to a net loss of $32.2 million in the first quarter of 2024, representing an improvement of $6.2 million or 19%, while adjusted EBITDA for the first quarter of 2025 was a loss of $16.9 million, versus an adjusted EBITDA loss of $23.7 million in the first quarter of 2024, an improvement of$6.8 million, or 29%.

Full Year 2025 Revenue Outlook

For fiscal year 2025, the Company continues to expect revenue in the range of $165 million to $175 million. This outlook assumes a high single-digit millions decline in our Americas academic revenue due to anticipated NIH funding pressures, no expected effect from U.S. export controls and limited impact from tariffs.

Conference Call Information

Standard BioTools will host a conference call and webcast on May 6th, 2025, at 4:30 p.m. ET to discuss the first quarter 2025 financial results. Live audio of the webcast will be available online along with an archived version of the webcast under the Events & Presentations page of the Company’s website.

Individuals interested in listening to the conference call may do so by dialing:

US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297

Use of Non-GAAP Financial Information

Standard BioTools has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company’s core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the Company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance, including with respect to future revenue; operational and strategic plans; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits and synergies of prior and potential future acquisitions, including the potential for such transactions to drive long-term profitable growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the anticipated benefits and synergies of prior and potential future acquisitions and the integration of any such businesses, including the potential for such transactions to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from such transactions; possible integration, restructuring and transition-related disruption resulting from such transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; anticipated NIH funding pressures; the expected effect from U.S. export controls and the expected impact from tariffs; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors� section of the Company’s annual report on Form 10-K filed with the SEC on March 11, 2025, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at or connect with us on X, Facebook®, LinkedIn, and YouTube�.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: .
Patent and License Information: .
Trademarks: . Any other trademarks are the sole property of their respective owners. ©2025 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Investor Contact:

STANDARD BIOTOOLS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended March31,
20252024
Revenue:
Product revenue$22,232$23,592
Services revenue17,60721,027
Collaboration and other revenue956921
Total revenue40,79545,540
Cost of revenue:
Cost of product revenue10,73012,781
Cost of services revenue10,3028,509
Cost of collaboration and other revenue2262
Total cost of revenue21,05421,352
Gross profit19,74124,188
Operating expenses:
Research and development11,32815,980
Selling, general and administrative38,70746,943
Restructuring and related charges1,5524,284
Transaction and integration expenses1,12417,163
Total operating expenses52,71184,370
Loss from operations(32,970)(60,182)
Bargain purchase gain25,213
Interest income2,9166,207
Interest expense(2)(1,033)
Other income (expense), net3,872(2,234)
Loss before income taxes(26,184)(32,029)
Income tax benefit (expense)151(128)
Net loss$(26,033)$(32,157)
Induced conversion of redeemable preferred stock(46,014)
Net loss attributable to common stockholders$(26,033)$(78,171)
Net loss per share attributable to common stockholders, basic and diluted$(0.07)$(0.27)
Shares used in computing net loss per share attributable to common stockholders, basic and diluted378,228294,125


STANDARD BIOTOOLS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
March31,December31,
2025
2024
ASSETS
Current assets:
Cash and cash equivalents$150,880$166,728
Short-term investments107,182126,146
Accounts receivable, net35,48033,608
Inventory42,12540,737
Prepaid expenses and other current assets8,3528,661
Total current assets344,019375,880
Inventory, non-current18,28118,528
Property and equipment, net43,59342,556
Operating lease right-of-use asset, net27,42228,828
Other non-current assets6,5066,301
Acquired intangible assets, net28,05728,954
Goodwill111,719111,297
Total assets$579,597$612,344
LIABILITIES AND STOCKHOLDERS� EQUITY
Current liabilities:
Accounts payable$11,778$12,282
Accrued liabilities21,97230,739
Operating lease liabilities, current6,3346,228
Deferred revenue, current12,76313,118
Deferred grant income, current3,3893,527
Total current liabilities56,23665,894
Convertible notes, non-current299299
Deferred tax liability1,0311,081
Operating lease liabilities, non-current24,89726,469
Deferred revenue, non-current32,54832,674
Deferred grant income, non-current6,5017,243
Other non-current liabilities3,4906,962
Total liabilities125,002140,622
Total stockholders� equity454,595471,722
Total liabilities and stockholders� equity$579,597$612,344


STANDARD BIOTOOLS INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Three Months Ended March31,
20252024
Operating activities
Net loss$(26,033)$(32,157)
Bargain purchase gain(25,213)
Stock-based compensation expense9,00911,611
Amortization of acquired intangible assets8982,106
Depreciation and amortization3,2733,088
Accretion of discount on short-term investments, net(841)(2,660)
Non-cash lease expense1,4381,446
Provision for excess and obsolete inventory815655
Change in fair value of warrants(232)853
Change in fair value of contingent consideration(3,400)
Other non-cash items385293
Changes in assets and liabilities, net(15,595)(22,498)
Net cash used in operating activities(30,283)(62,476)
Investing activities
Cash and restricted cash acquired in merger280,033
Purchases of short-term investments(32,321)(73,177)
Proceeds from sales and maturities of investments52,000112,000
Purchases of property and equipment(5,054)(781)
Net cash provided by investing activities14,625318,075
Financing activities
Repayment of term loan and convertible notes(8,192)
Payment of term loan fee(545)
Repurchase of common stock(11,051)
Payments for taxes related to net share settlement of equity awards and other(46)(17)
Proceeds from exercise of stock options72
Net cash used in financing activities(46)(19,733)
Effect of foreign exchange rate fluctuations on cash and cash equivalents357(21)
Net increase in cash, cash equivalents and restricted cash(15,347)235,845
Cash, cash equivalents and restricted cash at beginning of period168,81852,499
Cash, cash equivalents and restricted cash at end of period$153,471$288,344
Cash, cash equivalents, and restricted cash consists of:
Cash and cash equivalents$150,880$287,057
Restricted cash2,5911,287
Total cash, cash equivalents and restricted cash$153,471$288,344


STANDARD BIOTOOLS INC.
REVENUE
(In thousands)
(Unaudited)
Three Months Ended March31,
2025
2024
Product revenue:
Instruments$7,778$6,285
Consumables14,45417,307
Total product revenue22,23223,592
Service revenue:
Lab services12,10614,862
Field services5,5016,165
Total service revenue17,60721,027
Product and service revenue39,83944,619
Collaboration and other revenue956921
Total revenue$40,795$45,540


STANDARD BIOTOOLS INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(In thousands)
(Unaudited)
ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE
Three Months Ended March31,
20252024
Gross profit$19,741$24,188
Amortization of acquired intangible assets7171,956
Depreciation and amortization7361,024
Stock-based compensation expense495239
Loss on disposal of property and equipment32
Cost of sales adjustment(1,812)
Non-GAAP gross profit$21,721$25,595
Gross margin percentage48.4%53.1%
Amortization of acquired intangible assets1.8%4.3%
Depreciation and amortization1.7%2.3%
Stock-based compensation expense1.2%0.5%
Loss on disposal of property and equipment0.1%0.0%
Cost of sales adjustment0.0%(4.0)%
Non-GAAP gross margin percentage53.2%56.2%


STANDARD BIOTOOLS INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(In thousands)
(Unaudited)
ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES
Three Months Ended March31,
20252024
Operating expenses$52,711$84,370
Restructuring and related charges(1,552)(4,284)
Transaction and integration expenses(1,124)(17,163)
Stock-based compensation expense(8,514)(11,372)
Amortization of acquired intangible assets(181)(150)
Depreciation and amortization(2,537)(2,064)
Loss on disposal of property and equipment(154)(14)
Non-GAAP operating expenses$38,649$49,323
R&D operating expenses$11,328$15,980
Stock-based compensation expense(740)(1,328)
Depreciation and amortization(590)(871)
Loss on disposal of property and equipment(112)
Non-GAAP R&D operating expenses$9,886$13,781
SG&A operating expenses$38,707$46,943
Stock-based compensation expense(7,774)(10,044)
Amortization of acquired intangible assets(181)(150)
Depreciation and amortization(1,947)(1,193)
Loss on disposal of property and equipment(42)(14)
Non-GAAP SG&A operating expenses$28,763$35,542


STANDARD BIOTOOLS INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(In thousands)
(Unaudited)
ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA
Three Months Ended March31,
20252024
Net loss$(26,033)$(32,157)
Income tax (benefit) expense(151)128
Interest income(2,916)(6,207)
Interest expense21,033
Amortization of acquired intangible assets8982,106
Depreciation and amortization3,2733,088
Bargain purchase gain(25,213)
Restructuring and related charges1,5524,284
Transaction and integration expenses1,12417,163
Stock-based compensation expense9,00911,611
Cost of sales adjustment(1,812)
Loss on disposal of property and equipment18514
Other non-operating (income) expense(3,871)2,234
Adjusted EBITDA$(16,928)$(23,728)

FAQ

What were Standard BioTools (LAB) key financial results for Q1 2025?

Standard BioTools reported Q1 2025 revenue of $40.8M (down 10% YoY), net loss of $26.0M (improved 19%), and adjusted EBITDA loss of $16.9M (improved 29%). The company maintained $261M in cash with no material debt.

How much did Standard BioTools (LAB) reduce its operating expenses in Q1 2025?

Standard BioTools reduced operating expenses by 38% to $52.7M compared to Q1 2024, achieving $90M in total cost reductions since merger.

What is Standard BioTools (LAB) revenue guidance for full-year 2025?

Standard BioTools expects full-year 2025 revenue between $165-175 million, accounting for anticipated NIH funding pressures in Americas academic revenue.

How did Standard BioTools (LAB) different revenue segments perform in Q1 2025?

In Q1 2025, consumables revenue was $14.5M (down 16%), instruments revenue was $7.8M (up 24%), and services revenue was $17.6M (down 16%) year-over-year.

What was Standard BioTools (LAB) cash position as of March 31, 2025?

As of March 31, 2025, Standard BioTools had $261 million in cash and cash equivalents with no material debt.
STANDARD BIOTOOLS INC

NASDAQ:LAB

LAB Rankings

LAB Latest News

LAB Latest SEC Filings

LAB Stock Data

523.80M
373.92M
1.86%
73.11%
3.81%
Medical Devices
Laboratory Analytical Instruments
United States
SOUTH SAN FRANCISCO